Peroxisomal proliferator activated receptor-γ deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3)
2006

Study of a Genetic Mutation Linked to Familial Partial Lipodystrophy

Sample size: 2 publication Evidence: moderate

Author Information

Author(s): Francis Gordon A, Li Gang, Casey Robin, Wang Jian, Cao Henian, Leff Todd, Hegele Robert A

Primary Institution: University of Alberta

Hypothesis

Does the Y355X mutation in the PPARG gene contribute to familial partial lipodystrophy type 3 (FPLD3)?

Conclusion

The study identifies a novel PPARG mutation that leads to reduced PPAR-γ activity, contributing to the FPLD3 phenotype through haploinsufficiency.

Supporting Evidence

  • The Y355X mutation was identified in both the mother and daughter, linking it to their health issues.
  • The mutant protein was shown to be unstable and transcriptionally inactive.
  • Previous studies suggest that similar mutations in PPARG can lead to metabolic disturbances.

Takeaway

This study found a genetic change that makes a protein less effective, which can cause health problems related to fat storage in the body.

Methodology

DNA sequencing was performed to identify mutations in the PPARG gene, and various assays were conducted to assess the functionality of the mutant protein.

Limitations

The study is based on a small number of subjects, which may limit the generalizability of the findings.

Participant Demographics

The study involved a Canadian family with two affected individuals, a mother and her daughter.

Digital Object Identifier (DOI)

10.1186/1471-2350-7-3

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication